BOPH Revenue first quarter 2015 Y/Y Growth Comment
Bohai Pharmaceuticals Group, Inc. reported Revenue growth of 7.57% year on year in the first quarter 2015, to $ 54.74 millions, this is lower than Bohai Pharmaceuticals Group, Inc.'s recent average Revenue increase of 11.44%.
Looking into first quarter 2015 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Bohai Pharmaceuticals Group, Inc.' s Revenue increase of 7.57% ranks overall at the positon no. 1859 in the first quarter 2015.
BOPH Revenue ( Y/Y Growth %)
2015
2014
2013
2012
4th Quarter
June
-
12.48 %
-
-
3rd Quarter
March
-
14.17 %
-4 %
-
2nd Quarter
December
-
-5.52 %
-
-
1st Quarter
September
7.57 %
43.96 %
-
-
FY
-
15.34 %
318.85 %
-
Financial Statements
Bohai Pharmaceuticals Group,'s first quarter 2015 Revenue
Revenue by Quarter for the Fiscal Years 2012, 2013, 2014, 2015
Bohai Pharmaceuticals Group,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
24.96 %
-4.85 %
-100 %
(Sep 30 2013)
BOPH's I. Quarter Q/Q Revenue Comment
Bohai Pharmaceuticals Group, Inc. achieved in the I. Quarter 2015 above company average sequential Revenue jump of 19.53%, to $ 54.74 millions, from $45.80 millions in the fourth quarter.
Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Bohai Pharmaceuticals Group,'s Revenue growth quarter on quarter, overall rank is 705.
Bohai Pharmaceuticals Group, Inc. achieved in the I. Quarter 2015 above company average sequential Revenue jump of 19.53%, to $ 54.74 millions, from $45.80 millions in the fourth quarter.
Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Bohai Pharmaceuticals Group,'s Revenue growth quarter on quarter, overall rank is 705.
Bohai Pharmaceuticals Group,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2014)
12 Months Ending (Jun 30 2014)
12 Months Ending (Mar 31 2014)
12 Months Ending (Dec 31 2013)
12 Months Ending (Sep 30 2013)
Cumulative Revenue 12 Months Ending
$ 178.94
$ 175.09
$ 170.01
$ 165.07
$ 167.33
Y / Y Revenue Growth (TTM)
6.94 %
15.35 %
-
-
-
Year on Year Revenue Growth Overall
Ranking
# 869
# 1041
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
2.2 %
2.99 %
2.99 %
-1.35 %
10.24 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1122
# 1201
# 0
# 0
# 1169
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2014 period, Bohai Pharmaceuticals Group,'s cumulative twelve months Revenue were $ 179 millions, company would post below average annual Revenue growth of 10.24% year on year, if the fiscal year would end at Sep 30 2014. A slow-down in the Bohai Pharmaceuticals Group,'s Revenue growth from the 45.8% growth in Jun 30 2014.
In the Healthcare sector 128 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 869, from total ranking in previous quarter at 1041.
With the quarterly Revenue reported in the Sep 30 2014 period, Bohai Pharmaceuticals Group,'s cumulative twelve months Revenue were $ 179 millions, company would post below average annual Revenue growth of 6.94% year on year, if the fiscal year would end at Sep 30 2014. A slow-down in the Bohai Pharmaceuticals Group,'s Revenue growth from the 45.8% growth in Jun 30 2014.
In the Healthcare sector 128 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 869, from total ranking in previous quarter at 1041.
About Bohai Pharmaceuticals Group, Revenue Growth Rates (BOPH), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.21%